Early access
Sign in
Taking people in NorwayPhase 3

Tests added blood-thinning pills to prevent clots in pancreatic cancer patients

Tests whether adding antiplatelet medicine to standard clot prevention helps adults with pancreatic cancer.

Key facts

Who runs it
Akershus University Hospital
Where
Bodo, Drammen, Graalum, Lorenskog, and Trondheim, NorwaySee the 5 sites
Registry title
Antiplatelet therapy added to standard thromboprophylaxis to prevent thrombosis in pancreatic cancer patients - a randomized clinical trial (The PANART trial)
Status
Recruiting
Phase
Phase 3
People taking part
744 people, planned
Started
21 Aug 2025
Expected to end
16 Sept 2034
Type of study
Interventional
Record updated
13 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with pancreatic ductal cancer that is advanced, has spread or has come back. They get a blood-clot prevention drug with or without an added platelet-blocking drug.

Age
Over 18 years
Sex
All sexes can join
Disease stage
Pancreatic ductal adenocarcinoma that is locally advanced, has spread, or has returned after treatment meant to remove all of the disease.
Earlier treatment
Treatment for the cancer must be planned or already running. People having chemotherapy before planned surgery meant to remove all of the disease can join.

Main reasons for not taking part

  • Already taking antiplatelet drugs, or needing them but not yet started
  • Taking full-dose blood thinners, or needing them (people already on preventive blood thinners can join)
  • Platelet count under 30×10^9/L
  • Active bleeding or a high risk of severe bleeding
  • Serious liver disease, past heparin-induced low platelets, allergy to clopidogrel or dalteparin, or known pregnancy

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Participants are >18 years of age
  • Patients with locally advanced, metastatic or recurrent (after intended therapeutic treatment) pancreatic ductal adenocarcinoma
  • Patients where there is planned treatment or already receive treatment for their pancreatic ductal cancer
  • Patients receiving neoadjuvant chemotherapy before intended curative surgery

Who cannot take part

  • Known previous heparin induced thrombocytopenia – HIT
  • Current use of antiplatelet therapy or disease with indication for antiplatelet therapy not yet initiated
  • Known hypersensitivity to clopidogrel or dalteparin
  • Current use of full dose anti-coagulation or disease with indication of full dose anti-coagulation. Patients already on primary prophylaxis can be included
  • Known allergies to study medication
  • Active bleeding or severe risk of bleeding
  • Clinically significant liver disease (e.g., chronic active hepatitis, or cirrhosis)
  • Platelets <30×10^9/L
  • Known CYP2C19 genotype that influences clopidogrel metabolism (genotyping not necessary)
  • Severe intestinal malabsorption
  • Known pregnancy (pregnancy test is not necessary)

Where in Norway

  • Nordlandssykehuset HFBodo, NorwayTaking people
  • Drammen SykehusDrammen, NorwayTaking people
  • Sykehuset Oestfold HF KalnesGraalum, NorwayTaking people
  • Akershus University HospitalLorenskog, NorwayTaking people
  • St. Olavs hospital HFTrondheim, NorwayTaking people

About the trial

What the trial wants to find out

To investigate the efficacy and safety of adding antiplatelet theraphy to standard thromboprophylaxis on thrombotic disease in patients with pancreatic ductal cancer.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
Antiplatelet therapy added to standard thromboprophylaxis to prevent thrombosis in pancreatic cancer patients - a randomized clinical trial (The PANART trial)
Plain-language title
Tests added blood-thinning pills to prevent clots in pancreatic cancer patientsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
13 May 2026